Iveric bio will delay enrollment in its second pivotal clinical trial for Zimura due to the coronavirus global pandemic, the company announced in a press release.
Zimura (avacincaptad pegol), a novel complement C5 inhibitor, is being developed for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
“In light of the COVID-19 pandemic and out of an abundance of caution for the safety and well-being of our elderly patients and participating physicians and their staffs, we have decided to delay the initiation of enrollment in our second pivotal trial of Zimura in geographic atrophy secondary to dry AMD, the ISEE2008 trial, which was on track to begin this month,” Glenn P. Sblendorio, CEO and president of Iveric bio, said in the release. “It is critically important that we heed the warnings from the U.S. Centers for Disease Control, World Health Organization and national, state and local governments during this time of uncertainty. We will continue to closely monitor the situation in the United States and abroad to determine when enrollment should begin.”
Approximately 400 patients were to be enrolled in the multicenter, international, double-masked, sham-controlled trial.